Aldehyde oxidase 1 is highly abundant in hepatic steatosis and is downregulated by adiponectin and fenofibric acid in hepatocytes in vitro

Biochemical and Biophysical Research Communications

Volumn 350, Issue 3, 2006, Pages 731-735

  Neumeier, Markus ^a   Weigert, Johanna ^a   Schäffler, Andreas ^a   Weiss, Thomas S ^a   Schmidl, Christian ^a   Büttner, Roland ^a   Bollheimer, Cornelius ^a   Aslanidis, Charalampos ^a   Schölmerich, Jürgen ^a   Buechler, Christa ^a  

^a UNIVERSITY OF REGENSBURG   (Germany)

Author keywords

Adiponectin; Aldehyde oxidase 1; Fatty liver disease; Fenofibric acid; Hepatocyte; Peroxisome proliferator activated receptor

Indexed keywords

ADIPONECTIN; ALDEHYDE OXIDASE; FENOFIBRIC ACID; LEPTIN; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; REACTIVE OXYGEN METABOLITE; RECOMBINANT PROTEIN; XENOBIOTIC AGENT;

ANALYTIC METHOD; ARTICLE; CELL DAMAGE; COMPARATIVE STUDY; CONTROLLED STUDY; DOWN REGULATION; DRUG ACTIVITY; DRUG METABOLISM; ENZYME INHIBITION; FATTY LIVER; FIBROGENESIS; HUMAN; HUMAN CELL; IMMUNOBLOTTING; LIPID DIET; LIVER CELL; OBESITY; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; UPREGULATION;

ADIPONECTIN; ALDEHYDE OXIDOREDUCTASES; ANIMALS; CELLS, CULTURED; DOSE-RESPONSE RELATIONSHIP, DRUG; DOWN-REGULATION; FATTY LIVER; FENOFIBRATE; HEPATOCYTES; HUMANS; PROCETOFEN; RATS; RATS, WISTAR;

EID: 33749595358     PISSN: 0006291X     EISSN: 10902104     Source Type: Journal    
DOI: 10.1016/j.bbrc.2006.09.101     Document Type: Article

References (27)

1. Gil-Campos M., Canete R.R., and Gil A. Adiponectin, the missing link in insulin resistance and obesity. Clin. Nutr. 23 (2004) 963-974
2. Schaffler A., Scholmerich J., and Buchler C. Mechanisms of disease: adipocytokines and visceral adipose tissue-emerging role in nonalcoholic fatty liver disease. Nat. Clin. Pract. Gastroenterol. Hepatol. 2 (2005) 273-280
3. Xu A., Wang Y., Keshaw H., Xu L.Y., Lam K.S., and Cooper G.J. The fat-derived hormone adiponectin alleviates alcoholic and nonalcoholic fatty liver diseases in mice. J. Clin. Invest. 112 (2003) 91-100
4. Targher G., Bertolini L., Scala L., Poli F., Zenari L., and Falezza G. Decreased plasma adiponectin concentrations are closely associated with nonalcoholic hepatic steatosis in obese individuals. Clin. Endocrinol. (Oxf) 61 (2004) 700-703
5. Czaja M.J. Liver injury in the setting of steatosis: crosstalk between adipokine and cytokine. Hepatology 40 (2004) 19-22
6. Yamauchi T., Kamon J., Waki H., Terauchi Y., Kubota N., Hara K., Mori Y., Ide T., Murakami K., Tsuboyama-Kasaoka N., Ezaki O., Akanuma Y., Gavrilova O., Vinson C., Reitman M.L., Kagechika H., Shudo K., Yoda M., Nakano Y., Tobe K., Nagai R., Kimura S., Tomita M., Froguel P., and Kadowaki T. The fat-derived hormone adiponectin reverses insulin resistance associated with both lipoatrophy and obesity. Nat. Med. 7 (2001) 941-946
7. Fruchart J.C., and Duriez P. Mode of action of fibrates in the regulation of triglyceride and HDL-cholesterol metabolism. Drugs Today (Barc) 42 (2006) 39-64
8. Kadowaki T., and Yamauchi T. Adiponectin and adiponectin receptors. Endocr. Rev. 26 (2005) 439-451
9. Zang M., Zuccollo A., Hou X., Nagata D., Walsh K., Herscovitz H., Brecher P., Ruderman N.B., and Cohen R.A. AMP-activated protein kinase is required for the lipid-lowering effect of metformin in insulin-resistant human HepG2 cells. J. Biol. Chem. 279 (2004) 47898-47905
10. Sierksma A., Patel H., Ouchi N., Kihara S., Funahashi T., Heine R.J., Grobbee D.E., Kluft C., and Hendriks H.F. Effect of moderate alcohol consumption on adiponectin, tumor necrosis factor-alpha, and insulin sensitivity. Diabetes Care 27 (2004) 184-189
11. Kershaw E.E., and Flier J.S. Adipose tissue as an endocrine organ. J. Clin. Endocrinol. Metab. 89 (2004) 2548-2556
12. You M., Considine R.V., Leone T.C., Kelly D.P., and Crabb D.W. Role of adiponectin in the protective action of dietary saturated fat against alcoholic fatty liver in mice. Hepatology 42 (2005) 568-577
13. Shaw S., and Jayatilleke E. The role of aldehyde oxidase in ethanol-induced hepatic lipid peroxidation in the rat. Biochem. J. 268 (1990) 579-583
14. Pessayre D., Mansouri A., and Fromenty B. Nonalcoholic steatosis and steatohepatitis. V. Mitochondrial dysfunction in steatohepatitis. Am. J. Physiol. Gastrointest. Liver Physiol. 282 (2002) G193-G199
15. Thasler W.E., Weiss T.S., Schillhorn K., Stoll P.T., Irrgang B., and Jauch K.W. Charitable State-controlled foundation human tissue and cell research: ethic and Legal aspects in the supply of surgically removed human tissue for research in the academic and commercial sector in Germany. Cell Tissue Bank 4 (2003) 49-56
16. Weiss T.S., Pahernik S., Scheruebl I., Jauch K.W., and Thasler W.E. Cellular damage to human hepatocytes through repeated application of 5-aminolevulinic acid. J. Hepatol. 38 (2003) 476-482
17. Buechler C., Ullrich H., Aslanidis C., Bared S.M., Lingenhel A., Ritter M., and Schmitz G. Lipoprotein (a) downregulates lysosomal acid lipase and induces interleukin-6 in human blood monocytes. Biochim. Biophys. Acta 1642 (2003) 25-31
18. Buettner R., Parhofer K.G., Woenckhaus M., Wrede C.E., Kunz-Schughart L.A., Scholmerich J., and Bollheimer L.C. Defining high-fat-diet rat models: metabolic and molecular effects of different fat types. J. Mol. Endocrinol. 36 (2006) 485-501
19. Obach R.S., Huynh P., Allen M.C., and Beedham C. Human liver aldehyde oxidase: inhibition by 239 drugs. J. Clin. Pharmacol. 44 (2004) 7-19
20. Yamauchi T., Kamon J., Ito Y., Tsuchida A., Yokomizo T., Kita S., Sugiyama T., Miyagishi M., Hara K., Tsunoda M., Murakami K., Ohteki T., Uchida S., Takekawa S., Waki H., Tsuno N.H., Shibata Y., Terauchi Y., Froguel P., Tobe K., Koyasu S., Taira K., Kitamura T., Shimizu T., Nagai R., and Kadowaki T. Cloning of adiponectin receptors that mediate antidiabetic metabolic effects. Nature 423 (2003) 762-769
21. Kitamura S., Sugihara K., and Ohta S. Drug-metabolizing ability of molybdenum hydroxylases. Drug Metab. Pharmacokinet. 21 (2006) 83-98
22. Huang D.Y., and Ichikawa Y. Two different enzymes are primarily responsible for retinoic acid synthesis in rabbit liver cytosol. Biochem. Biophys. Res. Commun. 205 (1994) 1278-1283
23. Muto Y., Moriwaki H., Ninomiya M., Adachi S., Saito A., Takasaki K.T., Tanaka T., Tsurumi K., Okuno M., Tomita E., Nakamura T., and Kojima T. Prevention of second primary tumors by an acyclic retinoid, polyprenoic acid, in patients with hepatocellular carcinoma. Hepatoma Prevention Study Group. N. Engl. J. Med. 334 (1996) 1561-1567
24. Li C., and Wan Y.J. Differentiation and antiproliferation effects of retinoic acid receptor beta in hepatoma cells. Cancer Lett. 124 (1998) 205-211
25. Yeon J.E., Choi K.M., Baik S.H., Kim K.O., Lim H.J., Park K.H., Kim J.Y., Park J.J., Kim J.S., Bak Y.T., Byun K.S., and Lee C.H. Reduced expression of peroxisome proliferator-activated receptor-alpha may have an important role in the development of non-alcoholic fatty liver disease. J. Gastroenterol. Hepatol. 19 (2004) 799-804
26. Athyros V.G., Mikhailidis D.P., Didangelos T.P., Giouleme O.I., Liberopoulos E.N., Karagiannis A., Kakafika A.I., Tziomalos K., Burroughs A.K., and Elisaf M.S. Effect of multifactorial treatment on non-alcoholic fatty liver disease in metabolic syndrome: a randomised study. Curr. Med. Res. Opin. 22 (2006) 873-883
27. Harano Y., Yasui K., Toyama T., Nakajima T., Mitsuyoshi H., Mimani M., Hirasawa T., Itoh Y., and Okanoue T. Fenofibrate, a peroxisome proliferator-activated receptor alpha agonist, reduces hepatic steatosis and lipid peroxidation in fatty liver Shionogi mice with hereditary fatty liver. Liver Int. 26 (2006) 613-620